Showing results (291-300 of 1,607) with videos related to

Sort By:
Pageof 161
JAMA Oncology|December 10, 2017
Validation Study of the American Joint Committee on Cancer Eighth Edition Prognostic Stage Compared With the Anatomic Stage in Breast CancerAnna Weiss, Mariana Chavez-MacGregor, Daphne Y Lichtensztajn, et al.
JAMA Oncology|December 2, 2017
Trends in Cancer Survival by Health Insurance Status in California From 1997 to 2014Libby Ellis, Alison J Canchola, David Spiegel, et al.
JAMA Oncology|December 23, 2017
Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysisChee Khoon Lee, Johnathan Man, Sally Lord, et al.
JAMA Oncology|December 1, 2017
Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET StudyEli L Diamond, Vivek Subbiah, A Craig Lockhart, et al.
JAMA Oncology|March 2, 2018
Treatment Trends and Outcomes for Patients With Lymph Node-Positive Cancer of the PenisShreyas S Joshi, Elizabeth Handorf, David Strauss, et al.
JAMA Oncology|February 10, 2018
Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 AntibodiesJenny H Lee, Georgina V Long, Alexander M Menzies, et al.
JAMA Oncology|February 10, 2018
Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical TrialClara Montagut, Guillem Argilés, Fortunato Ciardiello, et al.
JAMA Oncology|March 10, 2018
Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical TrialJohn Mascarenhas, Ronald Hoffman, Moshe Talpaz, et al.
JAMA Oncology|March 10, 2018
Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer: The PREVAIL Randomized Clinical TrialDana E Rathkopf, Tomasz M Beer, Yohann Loriot, et al.
JAMA Oncology|February 17, 2018
Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical TrialIvana Sestak, Richard Buus, Jack Cuzick, et al.
Pageof 161